Repligen Co. (NASDAQ:RGEN) Shares Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP increased its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 717.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 61,398 shares of the biotechnology company's stock after acquiring an additional 53,884 shares during the period. Cinctive Capital Management LP owned approximately 0.11% of Repligen worth $8,838,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of RGEN. Groupama Asset Managment lifted its stake in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Repligen during the fourth quarter valued at approximately $52,492,000. Allspring Global Investments Holdings LLC grew its stake in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock worth $65,395,000 after buying an additional 203,011 shares during the period. Alliancebernstein L.P. increased its position in shares of Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after acquiring an additional 191,439 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Repligen in the 4th quarter valued at $24,034,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Repligen news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday. Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.64.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $0.65 during mid-day trading on Monday, hitting $112.59. The company had a trading volume of 875,586 shares, compared to its average volume of 687,270. Repligen Co. has a 12 month low of $104.98 and a 12 month high of $182.52. The stock has a market cap of $6.32 billion, a price-to-earnings ratio of -224.27, a PEG ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm's 50 day simple moving average is $150.03 and its two-hundred day simple moving average is $147.62.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.